Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 10/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24260224 | 0.89 | ELANE (0.45) | DRD2ADRB2MEN1KMT2ADRD3 | |
| SCHEMBL24260258 | 0.85 | KDM4E (0.49) | SSTR4SSTR1KDM4ETDP1DRD2 | |
| SCHEMBL24260561 | 0.83 | KAT2B (0.44) | MEN1KMT2A | |
| SCHEMBL24260504 | 0.81 | SSTR4 (0.50) | SSTR4SSTR1 | |
| SCHEMBL24260213 | 0.75 | CYP3A4 (0.44) | SSTR4SSTR1CHRM3KMT2ACYP3A4 | |
| SCHEMBL24260231 | 0.73 | PTGS2 (0.46) | KDM4ETDP1MEN1KMT2A | |
| SCHEMBL12415575 | 0.73 | KDM4E (0.55) | KDM4EKMT2A | |
| SCHEMBL24260613 | 0.73 | ELANE (0.47) | KDM4EDRD2ADRB2MEN1KMT2A | |
| SCHEMBL24260426 | 0.72 | ELANE (0.42) | TDP1DRD2MEN1KMT2ADRD3 | |
| SCHEMBL22605778 | 0.72 | ALDH1A1 (0.45) | KDM4ETDP1CHRM3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-11-21 | — | — | US | disclosed |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820727-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPV2, TRPV3 | SSTR4 1067/4885SSTR1 1810/4885KDM4E 3063/4885 |
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | SSTR4 1474/4885SSTR1 1480/4885KDM4E 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.